Compare Aecom (ACM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Vertex Pharmaceuticals Incorporated — how do they compare? Aecom trades at $66.76 (market cap $9.42B), while Vertex Pharmaceuticals Incorporated trades at $526.33 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.1× Aecom's market cap, and Aecom pays a 1.62% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ACM | VRTX | |
|---|---|---|
Market Cap | $9.42B | $132.79B |
Sector | Industrials | Health |
52-Week High | $134.35 | $529.65 |
52-Week Low | $66.86 | $376.62 |
Enterprise Value | $11.60B | $126.92B |
Dividend Yield | 1.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM trades at $75.84, up 1.21% daily, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings missed expectations with a loss of $0.50 per share, though revenue trends remain stable near $16 billion annually. The company secured new infrastructure projects in Australia and Portugal, supporting a record backlog. Valuation metrics show a P/E of 15.83 and P/S of 0.63, below sector averages, indicating potential undervaluation.
Outlook is mixed: strong analyst consensus (64% buy) and a $99.20 price target suggest 31% upside, but Q2 miss and rising debt-to-asset ratio (22.61% in 2025) pose risks. Investors should weigh robust contract wins against earnings volatility and macroeconomic pressures on infrastructure spending.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
